Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Berchuck

Showing results (191-200 of 681) with videos related to

Pageof 69
Sort By:
Cancer Prevention Research (Philadelphia, Pa.)|February 18, 2011
Reduction of ovarian and oviductal cancers in calorie-restricted laying chickensDonna K Carver, H John Barnes, Kenneth E Anderson, et al.
American Journal of Obstetrics and Gynecology|May 1, 2004
Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarraysAndrew Berchuck, Edwin S Iversen, Johnathan M Lancaster, et al.
Cancer Research|December 1, 1995
Microsatellite instability in gynecological sarcomas and in hMSH2 mutant uterine sarcoma cell lines defective in mismatch repair activityJ I Risinger, A Umar, J C Boyer, et al.
American Journal of Obstetrics and Gynecology|January 1, 1993
The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell linesG C Rodríguez, M P Boente, A Berchuck, et al.
Cancer Research|October 15, 1996
Cell cycle control of BRCA2J P Vaughn, F D Cirisano, G Huper, et al.
American Journal of Obstetrics and Gynecology|October 1, 1990
The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreductionV J Hunter, L Daly, M Helms, et al.
Journal of Cellular Biochemistry. Supplement|January 1, 1995
Molecular approaches to prevention and detection of epithelial ovarian cancerR C Bast, C M Boyer, F J Xu, et al.
Gynecologic Oncology|May 8, 2007
Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group studyAngeles Alvarez Secord, Kathleen M Darcy, Alan Hutson, et al.
Gynecologic Oncology|December 25, 2012
Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American womenDelores J Grant, Cathrine Hoyo, Lucy Akushevich, et al.
Gynecologic Oncology|September 1, 2020
Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancerRafael Gonzalez, Laura J Havrilesky, Evan R Myers, et al.
Pageof 69

Showing results (191-200 of 681) with videos related to

Sort By:
Pageof 69
Cancer Prevention Research (Philadelphia, Pa.)|February 18, 2011
Reduction of ovarian and oviductal cancers in calorie-restricted laying chickensDonna K Carver, H John Barnes, Kenneth E Anderson, et al.
American Journal of Obstetrics and Gynecology|May 1, 2004
Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarraysAndrew Berchuck, Edwin S Iversen, Johnathan M Lancaster, et al.
Cancer Research|December 1, 1995
Microsatellite instability in gynecological sarcomas and in hMSH2 mutant uterine sarcoma cell lines defective in mismatch repair activityJ I Risinger, A Umar, J C Boyer, et al.
American Journal of Obstetrics and Gynecology|January 1, 1993
The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell linesG C Rodríguez, M P Boente, A Berchuck, et al.
Cancer Research|October 15, 1996
Cell cycle control of BRCA2J P Vaughn, F D Cirisano, G Huper, et al.
American Journal of Obstetrics and Gynecology|October 1, 1990
The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreductionV J Hunter, L Daly, M Helms, et al.
Journal of Cellular Biochemistry. Supplement|January 1, 1995
Molecular approaches to prevention and detection of epithelial ovarian cancerR C Bast, C M Boyer, F J Xu, et al.
Gynecologic Oncology|May 8, 2007
Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group studyAngeles Alvarez Secord, Kathleen M Darcy, Alan Hutson, et al.
Gynecologic Oncology|December 25, 2012
Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American womenDelores J Grant, Cathrine Hoyo, Lucy Akushevich, et al.
Gynecologic Oncology|September 1, 2020
Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancerRafael Gonzalez, Laura J Havrilesky, Evan R Myers, et al.
Pageof 69